ble white crystal or powder, can be produced with a physical bulk similar to ordinary table sugar, and is 92% as sweet. In the U.S., based on over 10 years of animal, human, and other relevant use and safety data, Naturlose was determined to be Generally Recognized As Safe (GRAS) for use in foods as regulated by the Food Additives Amendment to the Federal Food, Drug, and Cosmetic Act. Naturlose has been approved as a "novel food ingredient" in the European Union (EU) without any restriction on usages. Nutraceutical or functional foods are foods with health-promoting or dietary management properties beyond the basic function of supplying nutrients and are a growing segment of the industry due to their increasing popularity with health-conscious consumers.
Spherix Incorporated was launched in 1967 as a scientific research company, under the name Biospherics Research. The company now leverages its scientific and technical expertise and experience through its two subsidiaries--Biospherics Incorporated and Spherix Consulting, Inc. Biospherics is currently running a Phase 3 clinical trial to study the use of Naturlose as a treatment for Type 2 diabetes. Its Spherix Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides. For more information, please visit www.spherix.com.
This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statePage: 1 2 3 4 5 6 Related medicine technology :1
. Spherix Reports First Quarter 2009 Earnings2
. Spherix Elects New Independent Director, and Elects Chairman of the Board3
. Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data4
. Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U.S.5
. Spherix D-tagatose to be Supplied by Inalco SpA6
. Growth Achieved in Spherixs Health Sciences Consulting Business7
. Spherix Reports Second Quarter Earnings8
. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies9
. GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting10
. CoAxia, Inc. Announces $21.5M Series D Financing11
. Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs